General
Preferred name
NELOTANSERIN
Synonyms
APD125 ()
PMID26609882-Compound-36 ()
APD-125 ()
P&D ID
PD058563
CAS
839713-36-9
Tags
available
drug candidate
Drug indication
Lewy body dementia
Sleep-wake disorder
Drug Status
investigational
Max Phase
Phase 2
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Nelotanser is Serotonin 2A receptor inverse agonist. In Aug 2016, Axovant Sciences initiated a phase-II clinical trial in Lewy body disease in USA.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
9
BOC Sciences Bioactive Compounds
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
ReFrame library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
20
Molecular Weight
436.03
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
4
Ring Count
3
Aromatic Ring Count
3
cLogP
4.78
TPSA
68.18
Fraction CSP3
0.11
Chiral centers
0.0
Largest ring
6.0
QED
0.62
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Neuroscience
Neuronal Signaling
Target
5-HT
5-HT Receptor
MOA
serotonin receptor inverse agonist
Solubility
DMSO: ≥ 32 mg/mL
Source data
